For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.
Community
Treatment
- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Treatment Centers
- Chemotherapy
- Immunotherapy
- Monoclonal Antibodies
- Radiotherapy
- Radioimmunotherapy
Understand
- Where to Start
- What is Lymphoma?
- The Lymphatic System
- Lymphoma Symptoms
- Lymphoma Causes
- Lymphoma Prognosis
- Lymphoma Stages
- Refractory/Relapsed Lymphoma
- Indolent lymphoma













Respiratory problems are a
Respiratory problems are a not uncommon consequence of receiving Rituxan. Sometimes referred to as the 'rituxan cough', this might manifest as an increased cough, as bronchospasm, dyspnea (or shortness of breath) or rhinitis (a runny nose). These reactions can occur during treatment or up to 12 months after you receive your last infusion. However, because Rituxan is considered a pneuomotoxin (www.pneumotox.com), you should bring this to the attention of your doctor immediately.
A cough is commonly
A cough is commonly associated with Rituxan and can some times last for months after treatment. However, occasionally Rituxan can induce interstitial pneumonitis. One of the attached research study estimates that this can occur in 9-14% of patients receiving rituximab chemotherapy. In most cases rituxan-induced interstitial pneumonitis is mild, but can become more severe. Terminating rituxan and treatment with glucocorticoids in combination with antibiotics are often prescribed for interstitial pneumonitis treatment. Here the links to some of the research studies I used to find this information.
https://www.medify.com/insights/article/19785875?utm_source=lymphomainfo...
https://www.medify.com/insights/article/18798110?utm_source=lymphomainfo...
Without looking at those
Without looking at those links I can at least say they sound consistent with the clinical trial data supplied by the manufacturer for the drug causing respiratory problems, which was 13%.